| Field | Value |
|---|---|
| NCT Number | NCT06757010 |
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | BioVie Inc. |
| Intervention | NE3107 (Bezisterim) |
| Mechanism | TNF-alpha inhibitor, anti-inflammatory |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |
| Indication | Early Parkinson's disease |
| Enrollment | 60 subjects (estimated) |
| Treatment Duration | 12 weeks |
| Dosage | 20 mg NE3107 BID (40 mg daily) vs. placebo |
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the hallmark motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability. Additionally, non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction significantly impact quality of life[1].
Despite decades of research, current treatments remain primarily symptomatic, focusing on dopamine replacement therapy with levodopa and dopamine agonists. While these interventions provide substantial benefit, they do not halt or slow disease progression. The development of disease-modifying therapies remains an urgent unmet need[2].
Neuroinflammation has emerged as a critical driver of PD pathogenesis. Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine that plays a central role in the neuroinflammatory processes contributing to dopaminergic neuron degeneration. Elevated TNF-α levels have been documented in the brains, cerebrospinal fluid, and peripheral blood of PD patients, correlating with disease severity and progression[3][4].
NE3107 (Bezisterim) is a novel oral TNF-alpha inhibitor developed by BioVie Inc. Unlike monoclonal antibody TNF inhibitors (such as infliximab, adalimumab, etanercept) that target TNF-α systemically, NE3107 is designed as a small molecule that can penetrate the blood-brain barrier and target neuroinflammation directly in the central nervous system[5].
The molecular mechanism involves:
NE3107 has demonstrated favorable pharmacological properties in preclinical studies:
The therapeutic landscape for TNF inhibition in neurodegeneration includes several approaches[6]:
| Drug | Type | BBB Penetration | Use in PD |
|---|---|---|---|
| NE3107 | Small molecule | Yes | Under investigation |
| Infliximab | Monoclonal antibody | Limited | Experimental |
| Etanercept | Recombinant protein | Limited | Experimental |
| Adalimumab | Monoclonal antibody | Limited | Experimental |
The key advantage of NE3107 is its small molecule design, which enables direct targeting of neuroinflammation in the brain rather than merely peripheral TNF-α.
TNF-α contributes to Parkinson's disease pathogenesis through multiple mechanisms[7]:
Studies support TNF-α inhibition as a therapeutic strategy for PD[4:1]:
The neuroprotective effects of TNF-α inhibition are mediated through[3:1]:
TNF-α plays a central role in PD pathogenesis through multiple pathways[2:1]:
Studies have demonstrated elevated TNF-α in PD patients:
The choice of an oral small molecule TNF inhibitor addresses key limitations of existing biologic therapies:
The trial focuses on early-stage Parkinson's disease for several important reasons:
Based on preclinical data, NE3107 may provide:
Potential risks include:
The targeted mechanism and small molecule design are expected to provide an acceptable risk-benefit profile.
For more detailed information, see related pages:
Several disease-modifying approaches are in development for PD:
| Approach | Target | Stage | Mechanism |
|---|---|---|---|
| NE3107 | TNF-α | Phase 2 | Anti-inflammatory, neuroprotective |
| Dapansutrile | NLRP3 | Phase 2 | Inflammasome inhibition |
| BiIB122 | LRRK2 | Phase 2 | Kinase inhibition |
| AMX0035 | TDP-43/mitochondrial | Phase 2/3 | Dual mechanism |
| Inosine | Urate | Phase 3 | Antioxidant |
Each approach targets different pathological mechanisms, and multiple successful therapies could potentially be combined for additive benefit.
The Phase 2 clinical trial of NE3107 (Bezisterim) for early Parkinson's disease (NCT06757010) represents an important step toward developing disease-modifying therapies for PD. By targeting TNF-α, a central mechanism of neuroinflammation, NE3107 offers a novel approach that addresses the underlying pathophysiology of PD rather than merely alleviating symptoms.
The scientific foundation supporting this trial includes:
Successful development of NE3107 would not only validate TNF-α inhibition as an effective PD therapy but also establish this approach as a viable strategy for other neurodegenerative disorders characterized by neuroinflammation.
Caldi E, Rossi C, Gallo A, et al. Peripheral inflammatory markers in Parkinson's disease. Brain Behav Immun. 2021. ↩︎
Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: The role of microglia and TNF-α. Neurobiol Dis. 2018. ↩︎ ↩︎
Bauer T, Miao Q, Shen J, et al. Neuroinflammation and TNF-α in Parkinson's disease: From pathogenesis to therapy. Aging Dis. 2020. ↩︎ ↩︎
Chen Y, Zhang L, Wang W, et al. TNF-α inhibition as a therapeutic strategy in Parkinson's disease. J Neuroinflammation. 2023. ↩︎ ↩︎
McGuire JL, Nguyen L, Li R, et al. Anti-TNF therapy for neurodegenerative disorders: Opportunities and challenges. Expert Opin Ther Targets. 2019. ↩︎
Bokhari SR, Zaman M, Ahmad M, et al. TNF-alpha inhibitors in neurodegeneration: A systematic review. CNS Drugs. 2023. ↩︎
Kaur K, Gill MS, Singh S, et al. TNF-alpha in Parkinson's disease: Current status and therapeutic perspectives. Brain Res Bull. 2022. ↩︎